Patient-reported outcomes (PROs) for tivozanib (TIVO) + nivolumab (NIVO) vs TIVO monotherapy in patients with renal cell carcinoma (RCC) following an immune checkpoint inhibitor (ICI): Results of the phase 3 TiNivo-2 study.Katy Beckermann, Bradley A. McGregor, Toni K. Choueiri et al.|Journal of Clinical Oncology|2025Cited by 0
Integrated efficacy and safety exposure response (ER) analysis of tivozanib (TIVO) for the treatment of renal cell cancer (RCC).Bradley A. McGregor, Robert J. Motzer, Edgar Braendle et al.|Journal of Clinical Oncology|2025Cited by 0
Efficacy of second line (2L) treatment with tivozanib (Tivo) as monotherapy or with nivolumab (Nivo) in patients (pts) with metastatic renal cell carcinoma (mRCC) previously treated with an immune checkpoint inhibitor (ICI) combination of ipilimumab (Ipi)/Nivo or vascular endothelial growth factor receptor-tyrosine kinase inhibitor (VEGFR-TKI)/ICI in the phase 3 TiNivo-2 study.Alex Chehrazi‐Raffle, Toni K. Choueiri, Pedro C. Barata et al.|Journal of Clinical Oncology|2025Cited by 0
46Integrated efficacy and safety exposure response (ER) analysis of tivozanib (TIVO) for the treatment of renal cell cancer (RCC)Bradley A. McGregor, Robert J. Motzer, Toni Choueri et al.|The Oncologist|2025Cited by 0